Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Meet the astronauts about to make history on flight around the moon - 2See the moon shine with Saturn in the southern sky after sunset Dec. 26
- 3Child influencers helped power a booming industry. It's time for a reckoning.
- 4At least 11 killed in South Africa mass shooting
- 5Help Your Efficiency with These Work area Updates
- The Best Computer games for Multiplayer Fun
- Dominating Monetary Administration: A Bit by bit Manual for Making an Individual Financial plan
- Dark matter obeys gravity after all — could that rule out a 5th fundamental force in the universe?
- The most effective method to Plan an Incineration Administration: A Bit by bit Guide.
- Why the chemtrail conspiracy theory lingers and grows – and why Tucker Carlson is talking about it
- Manual for Wonderful Getaway destination
- China's Normal Ponders: A Visual Excursion
- She's been a Bond girl and a mutant. Now she's grappling with Hollywood's obsession with 'eternal youth.'
- With more Moon missions on the horizon, avoiding crowding and collisions will be a growing challenge
